Headlines about Theravance Biopharma (NASDAQ:TBPH) have been trending somewhat positive on Wednesday, according to Accern. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Theravance Biopharma earned a news impact score of 0.22 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.0772949542175 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news articles that may have effected Accern’s rankings:
- Theravance Biopharma Inc to Post FY2017 Earnings of ($4.96) Per Share, Leerink Swann Forecasts (TBPH) (americanbankingnews.com)
- Theravance Biopharma (TBPH) Lifted to “Sell” at BidaskClub (americanbankingnews.com)
- Wired News – Theravance Biopharma Signs Global Collaboration Agreement with Janssen for TD-1473 (finance.yahoo.com)
- Theravance Biopharma Inc (TBPH) Expected to Announce Quarterly Sales of $3.71 Million (americanbankingnews.com)
- Theravance Biopharma Inc (TBPH) Given Consensus Rating of “Hold” by Analysts (americanbankingnews.com)
Shares of Theravance Biopharma (NASDAQ:TBPH) opened at $28.14 on Wednesday. The company has a market cap of $1,520.00, a P/E ratio of -5.45 and a beta of 2.09. Theravance Biopharma has a 52-week low of $22.90 and a 52-week high of $43.44. The company has a current ratio of 7.53, a quick ratio of 7.21 and a debt-to-equity ratio of 1.21.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.